Found: 49
Select item for more details and to access through your institution.
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
- Published in:
- Digestive Diseases & Sciences, 2024, v. 69, n. 6, p. 2165, doi. 10.1007/s10620-024-08410-z
- By:
- Publication type:
- Article
Colonic stenting as bridge to surgery versus emergency surgery for management of acute left-sided malignant colonic obstruction: a multicenter randomized trial (Stent-in 2 study).
- Published in:
- BMC Surgery, 2007, v. 7, p. 12, doi. 10.1186/1471-2482-7-12
- By:
- Publication type:
- Article
Multicentre study and systematic review: Allopurinol exposure during pregnancy.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 4, p. 503, doi. 10.1111/apt.18126
- By:
- Publication type:
- Article
Dietary index based on the Food Standards Agency nutrient profiling system and risk of Crohn's disease and ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 4, p. 558, doi. 10.1111/apt.17835
- By:
- Publication type:
- Article
Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1151, doi. 10.1111/apt.17719
- By:
- Publication type:
- Article
Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 1, p. 117, doi. 10.1111/apt.17248
- By:
- Publication type:
- Article
Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 6, p. 1044, doi. 10.1111/apt.17153
- By:
- Publication type:
- Article
Letter: loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease—authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 499, doi. 10.1111/apt.16757
- By:
- Publication type:
- Article
Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases – the longer the less? Authors' reply.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 54, n. 10, p. 1298, doi. 10.1111/apt.16605
- By:
- Publication type:
- Article
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti‐TNF treatment.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 1, p. 123, doi. 10.1111/apt.15745
- By:
- Publication type:
- Article
MATISSE: a method for improved single cell segmentation in imaging mass cytometry.
- Published in:
- BMC Biology, 2021, v. 19, n. 1, p. 1, doi. 10.1186/s12915-021-01043-y
- By:
- Publication type:
- Article
Publisher Correction to: MATISSE: a method for improved single cell segmentation in imaging mass cytometry.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
MATISSE: a method for improved single cell segmentation in imaging mass cytometry.
- Published in:
- BMC Biology, 2021, v. 19, n. 1, p. 1, doi. 10.1186/s12915-021-01043-y
- By:
- Publication type:
- Article
Pharmacological Activation of the Bile Acid Nuclear Farnesoid X Receptor Is Feasible in Patients with Quiescent Crohn's Colitis.
- Published in:
- PLoS ONE, 2012, v. 7, n. 11, p. 1, doi. 10.1371/journal.pone.0049706
- By:
- Publication type:
- Article
Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease.
- Published in:
- PLoS ONE, 2011, v. 6, n. 8, p. 1, doi. 10.1371/journal.pone.0023745
- By:
- Publication type:
- Article
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 9, p. 1, doi. 10.1007/s00262-024-03760-z
- By:
- Publication type:
- Article
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 12, p. 4049, doi. 10.1007/s00262-023-03541-0
- By:
- Publication type:
- Article
Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events.
- Published in:
- International Journal of Colorectal Disease, 2020, v. 35, n. 12, p. 2331, doi. 10.1007/s00384-020-03716-6
- By:
- Publication type:
- Article
PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Compartment-driven imprinting of intestinal CD4 T cells in inflammatory bowel disease and homeostasis.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 214, n. 3, p. 235, doi. 10.1093/cei/uxad095
- By:
- Publication type:
- Article
Exposure to Ambient Air Pollution and the Risk of Inflammatory Bowel Disease: A European Nested Case-Control Study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Optimizing Screening for Tuberculosis and Hepatitis B Prior to Starting Tumor Necrosis Factor-α Inhibitors in Crohn's Disease.
- Published in:
- Digestive Diseases & Sciences, 2014, v. 59, n. 3, p. 554, doi. 10.1007/s10620-013-2820-9
- By:
- Publication type:
- Article
Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 5, p. 1189, doi. 10.1002/cpt.1712
- By:
- Publication type:
- Article
Performance of EUS-FNA for mediastinal lymphadenopathy: impact on patient management and costs in low-volume EUS centers.
- Published in:
- Surgical Endoscopy & Other Interventional Techniques, 2010, v. 24, n. 9, p. 2260, doi. 10.1007/s00464-010-0946-9
- By:
- Publication type:
- Article
Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.
- Published in:
- Digestion, 2020, v. 101, n. 3, p. 245, doi. 10.1159/000499331
- By:
- Publication type:
- Article
A Pilot Study on Chemospecific Duodenal Visceral Sensitivity in Inflammatory Bowel Disease in Remission.
- Published in:
- Digestion, 2006, v. 73, n. 2/3, p. 151, doi. 10.1159/000094522
- By:
- Publication type:
- Article
Pooled Resequencing of 122 Ulcerative Colitis Genes in a Large Dutch Cohort Suggests Population-Specific Associations of Rare Variants in MUC2.
- Published in:
- PLoS ONE, 2016, v. 11, n. 8, p. 1, doi. 10.1371/journal.pone.0159609
- By:
- Publication type:
- Article
Chromogranin A regulates gut permeability via the antagonistic actions of its proteolytic peptides.
- Published in:
- Acta Physiologica, 2021, v. 232, n. 2, p. 1, doi. 10.1111/apha.13655
- By:
- Publication type:
- Article
Balloon dilatation with or without intralesional and oral corticosteroids for anastomotic Crohn's disease strictures.
- Published in:
- Journal of Gastrointestinal & Liver Diseases, 2015, v. 24, n. 4, p. 137
- By:
- Publication type:
- Article
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 9, p. 880, doi. 10.1111/apt.15689
- By:
- Publication type:
- Article
Earlier discontinuation of TNF‐α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 50, n. 4, p. 386, doi. 10.1111/apt.15380
- By:
- Publication type:
- Article
Off‐label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 49, n. 10, p. 1293, doi. 10.1111/apt.15229
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.
- Published in:
- Journal of Crohn's & Colitis, 2023, v. 17, n. 11, p. 1771, doi. 10.1093/ecco-jcc/jjad101
- By:
- Publication type:
- Article
Meat Intake Is Associated with a Higher Risk of Ulcerative Colitis in a Large European Prospective Cohort Studyø.
- Published in:
- Journal of Crohn's & Colitis, 2022, v. 16, n. 8, p. 1187, doi. 10.1093/ecco-jcc/jjac054
- By:
- Publication type:
- Article
Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series.
- Published in:
- Journal of Crohn's & Colitis, 2022, v. 16, n. 1, p. 91, doi. 10.1093/ecco-jcc/jjab124
- By:
- Publication type:
- Article
Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
- Published in:
- Journal of Crohn's & Colitis, 2021, v. 15, n. 11, p. 1920, doi. 10.1093/ecco-jcc/jjab081
- By:
- Publication type:
- Article
Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model.
- Published in:
- Journal of Crohn's & Colitis, 2021, v. 15, n. 5, p. 709, doi. 10.1093/ecco-jcc/jjaa219
- By:
- Publication type:
- Article
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
- Published in:
- Journal of Crohn's & Colitis, 2020, v. 14, n. 1, p. 33, doi. 10.1093/ecco-jcc/jjz119
- By:
- Publication type:
- Article
Corrigendum: Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.
- Published in:
- Journal of Crohn's & Colitis, 2018, v. 12, n. 11, p. 1381, doi. 10.1093/ecco-jcc/jjy083
- By:
- Publication type:
- Article
Genomic and Expression Analyses Identify a Disease-Modifying Variant for Fibrostenotic Crohn's Disease.
- Published in:
- Journal of Crohn's & Colitis, 2018, v. 12, n. 5, p. 582, doi. 10.1093/ecco-jcc/jjy001
- By:
- Publication type:
- Article
Fibre intake and the development of inflammatory bowel disease: A European prospective multi-centre cohort study (EPIC-IBD).
- Published in:
- Journal of Crohn's & Colitis, 2018, v. 12, n. 2, p. 129, doi. 10.1093/ecco-jcc/jjx136
- By:
- Publication type:
- Article
Controversies in Pouch Surveillance for Patients with Inflammatory Bowel Disease.
- Published in:
- Journal of Crohn's & Colitis, 2016, v. 10, n. 6, p. 747, doi. 10.1093/ecco-jcc/jjw035
- By:
- Publication type:
- Article
Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.
- Published in:
- Journal of Crohn's & Colitis, 2016, v. 10, n. 5, p. 549, doi. 10.1093/ecco-jcc/jjw002
- By:
- Publication type:
- Article
Low Fecal Calprotectin Predicts Sustained Clinical Remission in Inflammatory Bowel Disease Patients: A Plea for Deep Remission.
- Published in:
- Journal of Crohn's & Colitis, 2015, v. 9, n. 1, p. 50, doi. 10.1093/ecco-jcc/jju003
- By:
- Publication type:
- Article
Methotrexate accumulation in target intestinal mucosa and white blood cells differs from non‐target red blood cells of patients with Crohn's disease.
- Published in:
- Basic & Clinical Pharmacology & Toxicology, 2024, v. 135, n. 3, p. 308, doi. 10.1111/bcpt.14047
- By:
- Publication type:
- Article
High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2003, v. 98, n. 5, p. 1088, doi. 10.1111/j.1572-0241.2003.07414.x
- By:
- Publication type:
- Article
Homocysteine in Inflammatory Bowel Disease: A Risk Factor for Thromboembolic Complications?
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2000, v. 95, n. 10, p. 2825, doi. 10.1111/j.1572-0241.2000.03193.x
- By:
- Publication type:
- Article